{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:28:28Z","timestamp":1791509308841,"version":"4.3.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10072-024-07972-0","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T05:34:05Z","timestamp":1735796045000},"page":"2893-2896","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Eculizumab as rescue therapy for relapse of myasthenia gravis after immune-checkpoint inhibitors: a case report"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7393-4205","authenticated-orcid":false,"given":"Andrea","family":"Rigamonti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Mantero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Milani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Salmaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"issue":"9","key":"7972_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563\u2013580","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"7972_CR2","doi-asserted-by":"publisher","first-page":"fcad169","DOI":"10.1093\/braincomms\/fcad169","volume":"5","author":"A Farina","year":"2023","unstructured":"Farina A, Birzu C, Elsensohn MH et al (2023) Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Commun 5(3):fcad169","journal-title":"Brain Commun"},{"issue":"4","key":"7972_CR3","doi-asserted-by":"publisher","first-page":"e227722","DOI":"10.1001\/jamanetworkopen.2022.7722","volume":"5","author":"MZ Farooq","year":"2022","unstructured":"Farooq MZ, Aqeel SB, Lingamaneni P, Pichardo RC, Jawed A, Khalid S, Banskota SU, Fu P, Mangla A (2022) Association of immune checkpoint inhibitors with neurologic adverse events: a systematic review and meta-analysis. JAMA Netw Open 5(4):e227722","journal-title":"JAMA Netw Open"},{"issue":"12","key":"7972_CR4","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/onco.13931","volume":"26","author":"R Pathak","year":"2021","unstructured":"Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R (2021) Immune checkpoint inhibitor\u2013induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist 26(12):1052\u20131061","journal-title":"Oncologist"},{"issue":"12","key":"7972_CR5","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976\u2013986","journal-title":"Lancet Neurol"},{"issue":"5","key":"7972_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mus.22140","volume":"44","author":"S Muppidi","year":"2011","unstructured":"Muppidi S, Wolfe GI, Conaway MR et al (2011) MG-ADL: still a relevant outcome measure. Muscle Nerve 44(5):727\u2013731","journal-title":"Muscle Nerve"},{"key":"7972_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","volume":"70","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg 70:327\u2013334","journal-title":"Ann Thorac Surg"},{"key":"7972_CR8","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","volume":"74","author":"TM Burns","year":"2010","unstructured":"Burns TM, Conaway MR, Sanders DB et al (2010) The MG Composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 74:1434\u20131440","journal-title":"Neurology"},{"key":"7972_CR9","doi-asserted-by":"crossref","unstructured":"Burns TM, Conaway MR, Cutter GR et al (2008) Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve. 2008;38(2):957-963","DOI":"10.1002\/mus.21053"},{"issue":"10","key":"7972_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","volume":"18","author":"JC Kao","year":"2018","unstructured":"Kao JC, Brickshawana A, Liewluck T (2018) Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors. Curr Neurol Neurosci Rep 18(10):63","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"7972_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/jcm12010130","volume":"12","author":"C Marco","year":"2022","unstructured":"Marco C, Simo M, Alemany M et al (2022) Myasthenia gravis induced by immune checkpoint inhibitors: an emerging neurotoxicity in neuro-oncology practice: case series. J Clin Med 12(1):130","journal-title":"J Clin Med"},{"issue":"11","key":"7972_CR12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89(11):1127\u20131134","journal-title":"Neurology"},{"key":"7972_CR13","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3389\/fneur.2020.00634","volume":"11","author":"YT Huang","year":"2020","unstructured":"Huang YT, Chen YP, Lin WC, Su WC, Sun YT (2020) Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol 11:634","journal-title":"Front Neurol"},{"issue":"3","key":"7972_CR14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/mus.28037","volume":"69","author":"S Zadeh","year":"2024","unstructured":"Zadeh S, Price H, Drews R, Bouffard MA, Young LH, Narayanawami P (2024) Novel uses of complement inhibitors in myasthenia gravis-two case reports. Muscle Nerve 69(3):368\u2013372","journal-title":"Muscle Nerve"},{"issue":"1","key":"7972_CR15","doi-asserted-by":"publisher","first-page":"e200177","DOI":"10.1212\/NXI.0000000000200177","volume":"11","author":"C Nelke","year":"2023","unstructured":"Nelke C, Pawlitzki M, Kerkhoff R et al (2023) Immune checkpoint inhibition-related myasthenia-myositis-myocarditis responsive to complement blockade. Neurol Neuroimmunol Neuroinflamm 11(1):e200177","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"7972_CR16","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s10072-023-07190-0","volume":"45","author":"L Fionda","year":"2024","unstructured":"Fionda L, Rossini E, Lauletta A et al (2024) Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors. Neurol Sci 45(3):1243\u20131247","journal-title":"Neurol Sci"},{"issue":"5","key":"7972_CR17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/acn3.51761","volume":"10","author":"G Masi","year":"2023","unstructured":"Masi G, Pham MC, Karatz T et al (2023) Clinicoserological insights into patients with immunecheckpoint inhibitor-induced myasthenia gravis. Ann Clin Transl Neurol 10(5):825\u2013831","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07972-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07972-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07972-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T06:24:22Z","timestamp":1747376662000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07972-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["7972"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07972-0","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"30 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have potential conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The patient gave written informed consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}